Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
Active, not recruiting · NCT06543914
Conditions: Migraine
At a glance
- Research payments reported, 2025
- $384,402
- U.S. investigators named
- 12
- Sites paid
- 12
- Planned or actual enrollment
- 1,314
About the trial
- Sponsor
- AbbVie
- Dates
- Started 2024-11-26; completion 2029-02
- Results posted
- Not yet
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 1000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study across the world. Participants will receive atogepant oral tablets as prescribed per standard clinical practice and will be followed for 2 years. There is expected to be no additional burden for participants in this trial. P…
From ClinicalTrials.gov, last updated 2026-06-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $384,402 in research payments for this study in 2025 (71 payments).
Products named: Qulipta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Diane R. Counce, MD Neurology · Birmingham, AL
- Kerry Knievel, D.O. Neurology · Phoenix, AZ
- Andrew M. Blumenfeld, M.D. Neurology · Los Angeles, CA
- Kenneth P. Martinez, M.D. Neurology · Aliso Viejo, CA
- Michael D. Kohen, M.D. Allergy & Immunology · Daytona Beach, FL
- Timothy J. Wierzbicki, MD Neurology · Port Orange, FL
- Christopher Rhyne, M.D. Family Medicine · Louisville, KY
- Grace Forde, M.D. Pain Medicine · Great Neck, NY
- Jennifer W. Mcvige, M.D. Neurology · Amherst, NY
- Hsiangkuo Yuan, MD, PHD Neurology · Philadelphia, PA
- John F. Rothrock, MD Neurology · Fairfax, VA
- Brian D. Jenkins, D.O. General Practice · Neenah, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dent Neurosciences Research $61,040
- St Josephs Hospital and Medical Center, AZ $59,823
- Thomas Jefferson University $46,177
- The Los Angeles Headache Center $41,719
- Inova Fairfax Hospital, VA $34,389
- Neuroscience Group Sc $33,603
- Kenneth P Martinez MD $32,078
- Univ Clinical Research-Deland LLC $22,653
- Grace Ford MD PC $22,234
- Achieve Clinical Research LLC $22,182
- Norton Healthcare Inc $8,394
- Univ Clinical Research-De $110
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.